Evidence map›Paper›PMID 34541935›Full record

ReviewClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination.

M A Haimei

Abstract readReview
In one paragraph

Review in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Thrombosis After Adenovirus-Vectored COVID-19 Vaccination: A Concern on Underlying Illness.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

M A HaimeiBeijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.ORCID https://orcid.org/0000-0002-2715-7732

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the outbreak of Covid-19 in December, 2019, scientists worldwide have been committed to developing COVID-19 vaccines. Only when most people have immunity to SARS-CoV-2, COVID-19 can reduce even wholly overcome. So far, nine kinds of COVID-19 vaccines have passed the phase III clinical trials and have approved for use. At the same time, adverse reactions after COVID-19 vaccination have also reported. This paper focuses on the adverse effects of thrombosis and thrombocytopenia caused by the COVID-19 vaccine, especially the adenovirus-vector vaccine from AstraZeneca and Pfizer, and discusses its mechanism and possible countermeasures.

Indexed as

Genetic VectorsAdenoviridaeAntibodiesChAdOx1 nCoV-19COVID-19 VaccinesHumansPlatelet Factor 4Risk AssessmentRisk FactorsThrombocytopeniaThrombosisVaccinationAntibodiesChAdOx1 nCoV-19COVID-19 VaccinesPF4 protein, humanPlatelet Factor 4adenovirus-vectored vaccineadverse effectCOVID-19SARS-CoV-2thrombocytopeniathrombosis

Identifiers

PMID34541935
PMCPMC8642058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.